Blocking inflammation may offer a new treatment for difficult depression

A small trial suggests blocking inflammation might help treat difficult depression. Tocilizumab, an IL-6 receptor blocker, showed a suggestive pattern of improvement in patients with inflammation-linked depression. The study found that baseline hs-CRP levels, rather than IL-6, may help identify patients most likely to respond to this treatment. This supports larger trials for immune-targeted depression care. This proof-of-concept study involved 30 participants and suggests a potential new avenue for depression treatment, but larger, longer studies are needed for confirmation.